Adherence to Secondary Prevention Guidelines for Cardiovascular Risk

Consorci Sanitari de l'Alt Penedès i Garraf1 site in 1 country129 target enrollmentMarch 1, 2024

ConditionsAtherosclerosis Stroke, Ischemic Acute Coronary Syndrome Ischemic Heart Disease Peripheral Arterial Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Atherosclerosis
Sponsor: Consorci Sanitari de l'Alt Penedès i Garraf
Enrollment: 129
Locations: 1
Primary Endpoint: patients admitted for a cardiovascular event who are prescribed lipid-lowering treatment at discharge
Status: Completed
Last Updated: 4 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.

Registry

clinicaltrials.gov

Start Date

March 1, 2024

End Date

September 30, 2025

Last Updated

4 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Consorci Sanitari de l'Alt Penedès i Garraf

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Admitted to the cardiology, neurology, or general surgery departments
•With any of the following admission diagnoses:
•Non-ST-segment elevation acute coronary syndrome (NSTEACS) ST-segment elevation acute coronary syndrome (STEACS) Stable angina Unstable angina Non-ST-segment elevation myocardial infarction (NSTEMI) ST-segment elevation myocardial infarction (STEMI) Atherothrombotic ischemic stroke Lacunar stroke Peripheral artery disease Chronic ischemia of lower limbs Vascular ulcer due to arterial cause

Exclusion Criteria

•Patients for whom lipid-lowering treatment is ruled out due to limited life expectancy
•Patients likely to die during hospitalization
•Patients who died during hospitalization

Outcomes

Primary Outcomes

patients admitted for a cardiovascular event who are prescribed lipid-lowering treatment at discharge

Time Frame: Up to 3 months

Proportion of patients admitted for a cardiovascular event, warranting the initiation of secondary prevention with lipid-lowering agents, who are prescribed lipid-lowering treatment at discharge, adequate to reduce LDL by 50% or to below 55 mg/dL